American CryoStem Selected as "Incubator Company of the Year" by New Jersey Business Incubation Network (NJBIN)
09 Abril 2014 - 8:06AM
American CryoStem Corporation (OTCQB:CRYO), a
leading biotechnology developer and global licensor of patented
adipose tissue-based adult stem cell technologies, today announced
that the Company has been selected as an "Incubator Company of the
Year" by the New Jersey Incubation Network ("NJBIN"). The award
will be presented at NJBIN's upcoming Second Annual Business
Incubation Awards to be held on April 25, 2014 at the EcoComplex –
Rutgers University's Alternative Energy Innovation and
Environmental Research & Extension Center in Bordentown
Township, New Jersey.
John Arnone, CEO of American CryoStem commented, "We would like
to recognize and thank the NJBIN and the Burlington County High
Technology and Life Sciences Incubator for selecting our Company
for this award. Our ability to locate and develop our technology at
the Incubator has afforded us greater opportunities to build our
pipeline, create collaborations and widen our commercial
horizon."
NOTE TO PRESS: To arrange a one-on-one
interview with the Company, please contact Kathy Addison at
Hanover|Elite at 407-585-1080 or via email at
CRYO@hanoverelite.com.
About New Jersey Business Incubation
Network
The New Jersey Business Incubation Network (NJBIN) is a
collaborative statewide community of business experts and resource
facilities dedicated to enhancing the commercial success of early
stage and expansion stage entrepreneurial companies; growing higher
paying jobs, and supporting the economic growth strategy for the
state. Early stage and expansion stage companies receive critical
support services and flexible space in a professional business
environment. For more information, please visit NJBIN at
www.njbin.org.
About American CryoStem Corporation
A biotechnology pioneer in the fields of Regenerative and
Personalized Medicine, American CryoStem operates a
state-of-the-art, FDA-registered, clinical laboratory dedicated to
processing, bio-banking and development of cellular applications
using autologous adipose (fat) tissue and adipose derived stem
cells (ADSCs). Through its scientific efforts, the Company has
built a strong, strategic portfolio of intellectual property,
patent applications, and proprietary operating processes that form
its core standardized cellular platform. For more information,
please visit www.americancryostem.com and
www.acslaboratories.com. You can also find us on
Facebook and Twitter.
CONTACT: FOR MORE INFORMATION:
Hanover|Elite
Kathy Addison, Chief Operating Officer
407-585-1080 or via email at CRYO@hanoverelite.com
American Cryostem (CE) (USOTC:CRYO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
American Cryostem (CE) (USOTC:CRYO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about American Cryostem Corporation (CE) (OTCMarkets): 0 recent articles
Más de Artículos de Noticias